Table 2: Overall survival and values of nivolumab.
Nivo in 2nd-line | OS gains in days/grade (OS/gr) & HR | $C/LYG | Relative values (RV) (100,000/LYG) |
Nivo vs. Doc, squamous-NSCLC [4] | 96/B & 0.59 P = 0.00025 |
$488,524 | 0.20 |
Nivo vs. Doc, non-squamous- NSCLC, CheckMate 057 [5] | 84/C & 0.73 P = 0.0016 |
$558,326 | 0.18 |
Subset analysis in >10% positive PD-L1 | 264/A & 0.27 |
$177,645 | 0.56 |
Nivo, Atezo and Pembro demonstrated AEs gr ¾ of < 20%, maintained and/or improved the QoL and carried no black box warnings. The $C/LYG were weighed vs. $100,000, the acceptable Average Cost Effectiveness Ratio (ACER) in the US. Relative Values (RV) were computed as $100,000/C/LYG.